| 2025-12-19 |
详情>>
内部人交易：
Mottola Frank共交易4笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本5733.94万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.61美元,归母净利润-3444.5万美元,同比去年增长-158.84%
|
| 2025-11-04 |
财报披露：
美东时间 2025-11-04 盘后发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益0.19美元,归母净利润1067.20万美元,同比去年增长-46.75%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益-0.21美元,归母净利润-1182.7万美元,同比去年增长-9637.9%
|
| 2025-04-30 |
股东大会：
将于2025-06-16召开股东大会
会议内容 ▼▲
- 1.To elect two (2) directors to hold office for the ensuing three (3) years and until their successors have been duly elected and qualified;
2.To approve, on a non-binding basis, the compensation paid to our named executive officers;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2025-02-25 |
详情>>
业绩披露：
2022年年报每股收益1.13美元,归母净利润6071.10万美元,同比去年增长13.64%
|
| 2025-02-25 |
详情>>
业绩披露：
2024年年报每股收益1.34美元,归母净利润7386.50万美元,同比去年增长5512.84%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.06美元,归母净利润5853.70万美元,同比去年增长41415.60%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益0.30美元,归母净利润1611.70万美元,同比去年增长-51.86%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益0.37美元,归母净利润2004.00万美元,同比去年增长24.34%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益0.00美元,归母净利润12.40万美元,同比去年增长-99.27%
|
| 2024-04-29 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.To elect two directors to hold office for the ensuing three years and until their successors have been duly elected and qualified;
2.To approve, on a non-binding basis, the compensation paid to our named executive officers;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan and make certain technical updates;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2024-02-27 |
详情>>
业绩披露：
2023年年报每股收益0.02美元,归母净利润131.60万美元,同比去年增长-97.83%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.00美元,归母净利润14.10万美元,同比去年增长-99.6%
|
| 2023-05-01 |
股东大会：
将于2023-06-16召开股东大会
会议内容 ▼▲
- 1.To elect two (2) directors to hold office for the ensuing three (3) years and until their successors have been duly elected and qualified;
2.To approve, on a non-binding basis, the compensation paid to our named executive officers;
3.To approve, on a non-binding basis, the frequency of future advisory votes on executive compensation;
4.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2022-05-02 |
股东大会：
将于2022-06-17召开股东大会
会议内容 ▼▲
- 1.to elect two (2) directors to hold office for the ensuing three (3) years and until their successors have been duly elected and qualified;
2.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.to approve, on a non-binding basis, the compensation paid to our named executive officers;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.to elect two (2) directors to hold office for the ensuing three (3) years and until their successors have been duly elected and qualified;
2.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.to approve, on a non-binding basis, the compensation paid to our named executive officers;
4.to approve and adopt the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan in advance of expiration of the 2012 Equity Incentive Plan;
5.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2020-12-23 |
复牌提示：
2020-12-22 17:55:35 停牌，复牌日期 2020-12-22 18:35:00
|
| 2020-04-24 |
股东大会：
将于2020-06-15召开股东大会
会议内容 ▼▲
- 1.to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified;
2.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.to approve, on a non-binding basis, the compensation paid to our named executive officers;
4.to act upon a proposal to amend and restate the Supernus Pharmaceuticals, Inc. 2012 Equity Incentive Plan to increase the number of shares available under the plan;
5.to act upon a proposal to amend and restate the Supernus Pharmaceuticals, Inc. 2012 Employee Stock Purchase Plan to increase the number of shares available under the plan and to make certain technical and administrative changes;
6.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2019-04-29 |
股东大会：
将于2019-06-11召开股东大会
会议内容 ▼▲
- 1.to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified;
2.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to approve, on a non-binding basis, the compensation paid to our named executive officers;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified;
2.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to approve, on a non-binding basis, the compensation paid to our named executive officers;
4.to act upon a proposal to amend and restate the Supernus Pharmaceuticals, Inc. 2012 Equity Incentive Plan to make certain technical and administrative changes;
5.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2017-04-27 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified;
2.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.to approve, on a non-binding basis, the compensation paid to our named executive officers;
4.to approve, on a non-binding basis, the frequency of future advisory votes on executive compensation;
5.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|
| 2016-04-19 |
股东大会：
将于2016-05-19召开股东大会
会议内容 ▼▲
- 1.to elect three (3) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified;
2.to consider and act upon a proposal to amend and restate the Supernus Pharmaceuticals, Inc. 2012 Equity Incentive Plan to increase the number of shares available and to update the performance criteria for making awards under the plan;
3.to consider and act upon a proposal to amend and restate the Supernus Pharmaceuticals, Inc. 2012 Employee Stock Purchase Plan to increase the number of shares available under the plan;
4.to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
5.to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof.
|